Want to see GOSS full AI Analyst Report?
Top Page
Gossamer Bio
(NASDAQ:GOSS)
Select Model
Select Model
Rating:51Neutral
Price Target:
$0.21
▲(2.50% Upside)
Action:Reiterated
Date:08/27/26
The score is held back primarily by weak financial performance (large ongoing losses, heavy cash burn, and negative equity). Offsetting factors include a moderately improving near-term technical setup versus short-term moving averages and constructive regulatory/financing progress around the planned NDA submission, though regulatory uncertainty (missed prespecified alpha) and dilution/financing risks keep the overall rating near the middle of the range.
Positive Factors
Clinical efficacy and mechanistic support
Consistent directional benefits across the primary measure, secondary endpoints and imaging biomarkers strengthen the clinical rationale for seralutinib. These signals may support development and regulatory discussions despite the prespecified statistical miss.
Negative Factors
Persistent losses and cash burn
The company lacks recurring product revenue and continues to consume substantial cash while reporting deep losses and negative equity. This weak financial base limits flexibility and leaves long-term execution dependent on external financing or successful partnering.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical efficacy and mechanistic support
Consistent directional benefits across the primary measure, secondary endpoints and imaging biomarkers strengthen the clinical rationale for seralutinib. These signals may support development and regulatory discussions despite the prespecified statistical miss.
Read all positive factors
Gossamer Bio (GOSS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$99.97M
Dividend YieldN/A
Average Volume (3M)17.32M
Price to Earnings (P/E)―
Beta (1Y)1.39
Revenue Growth32.43%
EPS Growth7.40%
CountryUS
Employees162
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.57
Shares Outstanding488,846,700
10 Day Avg. Volume21,877,037
30 Day Avg. Volume17,317,995
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-5.77
Price to Sales (P/S)14.62
P/FCF Ratio-4.13
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$1.07Price Target Upside435.00% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-0.24
Revenue Forecast (FY)$38.39M
Gossamer Bio Business Overview & Revenue Model
Company Description
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002,...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Gossamer Bio has not historically relied on product sales as its primary source of revenue; instead, its earnings, when present, have typically come from collaboration-related arrangements and other p...
Gossamer Bio Earnings Call Summary
Earnings Call Date:May 18, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Nov 05, 2026
Earnings Call Sentiment Neutral
The call presented a mixed but constructive picture: clinically meaningful efficacy signals (including a traditional statistical threshold for 6MWD), supportive mechanistic CT FRI data across multiple lung compartments with clinical correlations, and decisive capital actions (debt reduction plan and cost containment) to preserve runway and focus on an NDA path. Counterbalancing these positives were key execution risks — the primary endpoint did not meet the prespecified alpha, a substantial workforce reduction was implemented, cash runway is short ($99M to Q1 2027), and the debt exchange depends on high noteholder participation and involves tradeoffs. Overall, the tone is cautious and pragmatic, emphasizing strengthened conviction in the program but acknowledging material near-term financial and regulatory risks.Positive Updates
Clinical Efficacy: 6-Minute Walk Distance Improvement
PROSERA Phase III showed a placebo-adjusted improvement of 13.3 meters in 6-minute walk distance (6MWD) at week 24: seralutinib improved 28.2 m from baseline vs 13.5 m for placebo (p = 0.032). The result met the traditional 0.05 significance threshold.
Negative Updates
Missed Prespecified Statistical Threshold
While the primary 6MWD p-value was 0.032 (meeting p<0.05), it did not meet the prespecified alpha of 0.025 required by the study design, creating regulatory and interpretive uncertainty for the primary endpoint.
Read all updates
Q1-2026 Updates
Positive
Negative
Clinical Efficacy: 6-Minute Walk Distance Improvement
PROSERA Phase III showed a placebo-adjusted improvement of 13.3 meters in 6-minute walk distance (6MWD) at week 24: seralutinib improved 28.2 m from baseline vs 13.5 m for placebo (p = 0.032). The result met the traditional 0.05 significance threshold.
Read all positive updates
Company Guidance
The company provided clear near‑term regulatory, clinical and financial guidance: a Type B pre‑NDA meeting (in‑person; briefing book submitted after an April 2026 request) is scheduled for mid‑June 2026 and the NDA submission target remains September 2026 (pathway: one adequate and well‑controlled study + confirmatory evidence from PROSERA and TORREY), with a potential approval in Q3 2027 if the meeting proceeds as expected; clinically, PROSERA showed a placebo‑adjusted 6‑minute walk distance benefit of 13.3 m at week 24 (seralutinib +28.2 m vs placebo +13.5 m; p=0.032, did not meet prespecified alpha 0.025), all four key secondaries favored seralutinib, a stronger effect was seen in a prespecified risk‑enriched subgroup, and the CT FRI substudy enrolled 162 patients with 125 evaluable paired scans at week 24 showing statistically significant multi‑compartment arterial, venous, fibrosis‑like and complexity remodeling signals; financially, cash and marketable securities totaled $99M as of March 31, 2026 with runway to Q1 2027, the company has cut operating expenses (including a reduction in force affecting ~50% of staff) and proposes a convertible note exchange that would reduce convertible debt from $200M to $72M (a $128M reduction), extend maturity to 2030, issue new secured notes bearing 7.5% cash interest paid semiannually secured by a first‑priority lien, and requires minimum 98% participation (may be waived).Gossamer Bio Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 53.29M | 48.47M | 114.70M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 53.05M | 47.47M | 114.70M | 0.00 | 0.00 | 0.00 |
| EBITDA | -204.98M | -158.47M | -39.97M | -161.92M | -211.07M | -209.40M |
| Net Income | -125.22M | -170.37M | -56.53M | -179.82M | -229.38M | -234.00M |
Balance Sheet | ||||||
| Total Assets | 76.87M | 172.25M | 315.29M | 311.92M | 272.45M | 343.66M |
| Cash, Cash Equivalents and Short-Term Investments | 57.03M | 136.93M | 294.52M | 296.43M | 255.68M | 325.22M |
| Total Debt | 39.10M | 202.91M | 202.88M | 212.46M | 225.74M | 185.24M |
| Total Liabilities | 170.90M | 295.01M | 285.80M | 249.15M | 260.37M | 222.19M |
| Stockholders Equity | -94.03M | -122.76M | 29.49M | 62.77M | 12.08M | 121.46M |
Cash Flow | ||||||
| Free Cash Flow | -162.63M | -171.34M | -3.47M | -159.16M | -187.51M | -190.51M |
| Operating Cash Flow | -162.63M | -171.27M | -3.47M | -159.16M | -187.03M | -188.89M |
| Investing Cash Flow | 174.48M | 156.36M | 29.02M | -110.97M | -1.03M | -117.43M |
| Financing Cash Flow | 3.19M | 6.42M | -11.49M | 190.15M | 117.09M | 3.33M |
Gossamer Bio Risk Analysis
Gossamer Bio disclosed 80 risk factors in its most recent earnings report. Gossamer Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Gossamer Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $99.97M | -0.31 | 108.75% | ― | 32.43% | 7.40% | |
51 Neutral | $154.29M | -2.65 | -150.47% | ― | ― | ― | |
46 Neutral | $263.51M | -2.24 | -531.04% | ― | -82.91% | 6.27% | |
45 Neutral | $194.40M | -1.07 | -1032.19% | ― | 354.37% | -63.33% | |
42 Neutral | $93.51M | -4.03 | -53.14% | ― | ― | 54.84% |
* Healthcare Sector Average
GOSS
Gossamer Bio
0.17
-2.23
-92.92%
ALDX
Aldeyra Therapeutics
1.54
-4.32
-73.72%
CUE
Cue Biopharma
28.16
4.11
17.11%
TLSA
Tiziana Life Sciences
1.08
-0.75
-40.98%
ALEC
Alector
2.39
0.00
0.00%
CNTB
Connect Biopharma Holdings
2.28
0.52
29.55%
Gossamer Bio Corporate Events
Private Placements and FinancingRegulatory Filings and Compliance
Gossamer Bio Amends Charter for New Preferred Financing
Positive
Aug 26, 2026
On August 24, 2026, Gossamer Bio, Inc. amended its certificate of incorporation in Delaware to implement the previously disclosed designation for its Series A-1 Convertible Preferred Stock, tied to the closing of a previously announced private pla...
Business Operations and StrategyPrivate Placements and Financing
Gossamer Bio Secures Major Seralutinib Regulatory Financing Deal
Positive
Aug 21, 2026
On August 20, 2026, Gossamer Bio entered into a structured private placement of up to approximately $250 million, built around milestone-based pre-funded and approval-linked warrants to finance seralutinib’s path through U.S. regulatory revi...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related AnnouncementsRegulatory Filings and ComplianceShareholder MeetingsStock Split
Gossamer Bio Reclaims Seralutinib Rights and Control
Positive
Jul 27, 2026
On July 23, 2026, Gossamer Bio terminated its collaboration and license agreement with Chiesi and signed a rights reacquisition deal that returns worldwide development and commercial control of seralutinib to Gossamer, including for pulmonary arte...
Private Placements and Financing
Gossamer Bio Sets Conversion Terms for Convertible Notes
Negative
Jul 1, 2026
On July 1, 2026, Gossamer Bio announced the initial conversion rate for its 7.50% Convertible Senior Secured First Lien Notes due 2030 at 5,347.5936 shares of common stock per $1,000 principal amount, implying a conversion price of about $0.19 per...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and ComplianceShareholder Meetings
Gossamer Bio Announces Final Convertible Notes Exchange Results
Positive
Jun 17, 2026
On June 17, 2026, Gossamer Bio announced the final results of its exchange offer and consent solicitation for its 5.00% Convertible Senior Notes due 2027, a key step in reshaping its balance sheet. The company offered holders a mix of up to $72 mi...
Executive/Board ChangesShareholder Meetings
Gossamer Bio shareholders reaffirm board and governance structure
Positive
Jun 5, 2026
At its 2024 annual meeting, Gossamer Bio shareholders re-elected Faheem Hasnain and Russell Cox as Class II directors to three-year terms expiring at the 2029 annual meeting, reinforcing continuity in the company’s board leadership. Investor...
Business Operations and StrategyPrivate Placements and Financing
Gossamer Bio Restructures Capital Through Convertible Notes Exchange
Neutral
Jun 5, 2026
On June 3, 2026, Gossamer Bio reported early tender results for its exchange offer and consent solicitation involving its 5.00% Convertible Senior Notes due 2027, with $181.1 million, or 90.526%, of the notes tendered by June 2 and accepted for ea...
Business Operations and StrategyPrivate Placements and Financing
Gossamer Bio Extends Early Deadline in Note Exchange
Neutral
Jun 2, 2026
On June 2, 2026, Gossamer Bio, Inc. extended the early tender deadline for its ongoing exchange offer and consent solicitation for its 5.00% Convertible Senior Notes due 2027 to 5:00 p.m. New York City time that same day, while keeping the overall...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.